2011 CMHC Online CME2011 CMHC Online CME
 
2011 Home
Program Menu
Accreditation
Credit Instructions
Faculty Bios
Faculty Disclosures
Supporters
Edit Profile
Contact Us
2012 CMHC Info
Share

 

 

 

Home :: Registration
Registration is required to view online educational activities. Once registered, you will receive an email with your username and password.
Email Address: Confirm Email Address:
First Name: Last Name: MI:
Degree:
Specialty:
Address1:
Address2:
City: State: Zip:
Telephone:
License number:
State of license:
Please check which credit
you are requesting:
ACCME   CDR   ANCC
Yes, I would like to join the
CMHC Mailing List
spacer
Please Read & Agree to the Terms and Conditions Below

The 2011 Cardiometabolic Health Congress Enduring Activities is jointly sponsored by
HealthScience Media, Inc. and Medical Education Resources, Inc.


Release and Expiration Dates: December 12, 2011 to December 12, 2012
Each activity will take approximately 2 hours to complete.

Statement of Need
The prevalence of cardiometabolic risk continues to rise in the United States. In the years ahead, American physicians should expect to treat unprecedented numbers of patients at high risk for morbidity and mortality from cardiovascular disease. In 2000, approximately 32% of U.S. adults had metabolic syndrome, a constellation of cardiometabolic risk factors including excessive abdominal fat, insulin resistance, dyslipidemia, and hypertension. Today, that figure has climbed to 34% and may even be as high as 38%, depending on the criteria used to define the syndrome.

Cardiometabolic Risk Factors Are Undertreated and Difficult to Manage
Despite the well-documented risks of unchecked diabetes, obesity, hypertension, and dyslipidemia, these conditions are commonly undertreated. Even when treated, they remain stubbornly difficult to manage:

  • Half or more of patients with diabetes fail to meet recommended target HbA1c goals. An analysis of data from the National Health and Nutrition Examination Survey reported that only 50% of treated patients achieve the American Diabetes Association’s recommended HbA1c target of 7% or less. In addition, a report released by the American Association of Clinical Endocrinologists said that two out of three patients with type 2 diabetes were not achieving the association’s recommended HbA1c goal of 6.5%.
  • When it comes to first-line therapy for obesity – diet and exercise – few patients succeed, and any improvements are usually modest. Current pharmacotherapy options are limited.  Available obesity drugs have, to date, produced only modest weight loss in most patients and have been linked to adverse gastrointestinal effects and mood disorders.
  • Only 71% of patients with hypertension are receiving any form of treatment. Of these, less than half (48%) have their blood pressure under control; hypertension remains uncontrolled in 52% of treated patients.
  • Less than half of those who qualify for any kind of lipid-modifying treatment to reduce the risk of coronary heart disease are receiving it. In fact, less than half of even the highest-risk individuals, those with symptomatic coronary heart disease, are receiving lipid-lowering treatment. Of those being treated, only about one-third are achieving target goals.

Conclusion
Healthcare professionals play a major role in stemming these health consequences and associated costs by employing aggressive strategies for the early identification and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The 2011 Cardiometabolic Health Congress will translate the latest cutting-edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk. The goal is to provide the medical community with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.

Target Audience & Learning Objectives
The CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk. Each symposium has its own specific learning objectives which will be viewed before participating in the educational activity.
At the end of the congress, participants will be able to:

  • Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.
  • Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
  • Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles.
  • Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.
Physician Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources designates each enduring material for a maximum of 2 AMA PRA Category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Each CE activity provides 2 contact hours of continuing nursing education.

CA Board of Registered Nursing
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299,
for 2 contact hours per activity.


Registered Dietitian Accreditation

Each program has been approved by the Commission on Dietetic Registration for 2 CPEUs.

There is no fee for this educational activity. The media for this educational activity is the Internet.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental ­design, data collection, and analysis.

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

Name of Content Manager
Reported Financial Relationship
Dina Kouveliotes, HealthScience Media No financial relationships to disclose
Jeff Minerd, HealthScience Media No financial relationships to disclose
Julie Johnson, PharmD, MER No financial relationships to disclose
Steven Scharmann, MD, MER No financial relationships to disclose
Veronda Smith, BC-FNP, MER No financial relationships to disclose

Faculty disclosures can be viewed by clicking the “Faculty Disclosures” link found on the left side menu.

Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources and/or HealthScience Media, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, HealthScience Media, Inc. and/or the various industry supporters. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Instructions for Receiving Credit
Viewers are expected to view all presentations that are part of a symposium before attempting to complete the post-test and activity evaluation for that symposium. Successful completion will lead to the issuance of a certificate for 2 AMA PRA Category 1 Credit(s)™ per symposium -
there are 11 total. To receive credit, the course must be completed before December 12, 2012. If you attended the live presentation on
October 19-22, 2011, and have received CME credit for this program, you are not eligible for additional credit.

There are no fees for participating in and receiving CME credit for this activity. During the period December 12, 2011 through December 12, 2012, participants must follow these steps in order to receive CME/CE credit:

  • Sign In or Register
  • Read and accept the Terms & Conditions including the learning objectives and faculty disclosures
  • View and study the educational activity
  • Complete the post-test by recording the best answer to each question in the answer key
  • Complete the evaluation form
  • After successfully completing the online test and evaluation, your application will automatically be submitted to the CME/CE provider for processing. Your statement of credit will be mailed to you within 4-6 weeks.

Policy on Privacy and Confidentiality
Medical Education Resources, Inc. (MER), protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors.  MER and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the appropriate accrediting agency.

MER and HealthScience Media maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your non-public personal information.

MER can be contacted by e-mail at data@mer.org or by telephone at 303-798-9682.

MERlogo HSMlogo
This activity is jointly sponsored by Medical Education Resources and HealthScience Media, Inc.

Hardware and Software Requirements
This online activity must be viewed with Firefox or Internet Explorer 6.0 or later. If you do not have these browsers, you can download Firefox here and Internet Explorer here. Viewing also requires Windows Media Player which can be downloaded here. Optimal viewing requires a broadband connection of at least 1 Mbps and a 1 GHz processor with 1 GB RAM.

Faculty Disclosures
George L. Bakris, MD
Grants/Research Support: Juvenile Diabetes Research Foundation; NIDDK/NIH; GlaxoSmithKline; Forest Labs; CVRx
Consultant: GlaxoSmithKline; Merck; Novartis; Boehringer Ingelheim; Takeda; Abbott; Walgreens; BMS/sanofi; Gilead; Forest
Speakers Bureau: Novartis; Forest; GlaxoSmithKline

Christie M. Ballantyne, MD
Grants/Research Support: Abbott; AstraZeneca; GlaxoSmithKline; Merck; sanofi-Synthelabo; Schering-Plough; Takeda; NIH; ADA; American Heart Association
Consultant: Abbott; Amylin Pharmaceuticals; Bristol-Myers Squibb; Kowa; Merck/Schering-Plough; Metabasis; Novartis; Pfizer; Resverlogix; Roche; sanofi-Synthelabo; Schering-Plough; Takeda
Speakers Bureau: Merck/Schering-Plough; Pfizer; Schering-Plough

Robert H. Eckel, MD
Grants/Research Support: sanofi-aventis; diaDexus; GlaxoSmithKline
Consultant: Johnson & Johnson; Eli Lilly; Pfizer; Esperion; GTC Nutrition; Amylin Pharmaceuticals; Genfit
Speakers Bureau: None
Other Financial Support: CME Incite; Voxmedia; Vindico; Intellyst; CMHC

Jay S. Skyler, MD, MACP
Grants/Research Support: Bayhill Therapeutics; Halozyme; Intuity; Osiris Therapeutics
Consultant: BD Technologies; Ideal Life; Mannkind; sanofi-aventis; Valeritas; Viocyte; Veroscience
Speakers Bureau: None
Board of Directors: Amylin Pharmaceuticals; DexCom; Opko Health; Moerae Matrix Inc
Stock/Shareholder: Amylin Pharmaceuticals; DexCom; Opko Health; Patton Medical Devices; Tandem Diabetes Care
Scientific Lecture Support: sanofi-aventis; Veroscience

Martin Abrahamson, MD
Grants/Research Support: None
Consultant: Novo Nordisk; Halozyme; Boehringer Ingelheim; Merck
Speakers Bureau: None

David Aguilar, MD
Grants/Research Support: None
Consultant: Amylin Pharmaceuticals
Speakers Bureau: None

David Badesch, MD
Grants/Research Support: Actelion/CoTherix; Gilead/Myogen; Pfizer; United Therapeutics/Lung RX; Eli Lilly/ICOS; Bayer; Novartis
Consultant: Actelion/CoTherix; Gilead/Myogen; Pfizer; Mondo Biotech/MonoGEN; United Therapeutics/Lung RX; Eli Lilly/ICOS; Bayer; Ikaria; Arena
Stock/Shareholder: Johnson & Johnson
Speakers Bureau: None

Harold Bays, MD
Grants/Research Support: Amarin; GlaxoSmithKline; Omthera
Consultant: Amarin; GlaxoSmithKline
Speakers Bureau: GlaxoSmithKline

Eliot Brinton, MD
Grants/Research Support: Merck; Abbott
Consultant: Kowa; Merck
Speakers Bureau: Kowa; Merck; Abbott; GlaxoSmithKline; Takeda; Bristol-Myers Squibb; Boehringer Ingelheim

John Buse, MD, PhD
Grants/Research Support: Amylin Pharmaceuticals; Andromeda; Novo Nordisk; Medtronic MiniMed, Inc; Eli Lilly; Tolerex; Halozyme; Pfizer; Hoffman LaRoche; sanofi-aventis; Johnson & Johnson; Transition Therapeutics
Consultant: Novo Nordisk; Amylin Pharmaceuticals; Eli Lilly; Hoffman LaRoche; Bayhill Therapeutics; LipoScience; Exsulin; GI Dynamics; Biodel; Diartis; Merck; Osiris Therapeutics; Orexigen; TransPharma
Speakers Bureau: None

Christopher Cannon, MD
Grants/Research Support: Accumetrics; AstraZeneca; GlaxoSmithKline; Intekrin Therapeutics; Merck; Takeda
Consultant: Bristol-Myers Squibb/sanofi-aventis; Novartis; Alnylam; Automedics Medical Systems
Speakers Bureau: None
Stock/Shareholder: Automedics Medical Systems

William Cromwell, MD
Grants/Research Support: Isis Pharmaceuticals; Genzyme
Consultant: Genzyme; Health Diagnostic Laboratories; LabCorp
Speakers Bureau: Abbott; Kowa; Liposcience; Merck

Tara Dall, MD
Grants/Research Support: None
Consultant: None
Speakers Bureau: Abbott; GlaxoSmithKline; Santarus; Liposcience

Jaime Davidson, MD
Grants/Research Support: AstraZeneca; Bristol-Myers Squibb
Consultant: Eli Lilly & Company; Johnson & Johnson (Lifescan); Merck-Sharp and Dome; Novo Nordisk; Takeda; Boehringer Ingelheim; Halozyme
Speakers Bureau: Bayer; Eli Lilly & Company; Roche Diagnostics; Johnson & Johnson (Lifescan); Novo Nordisk; Boehringer Ingelheim; Novartis; Merck-Serono

Michael Davidson, MD
Grants/Research Support: Abbott; Daiichi Sankyo; GlaxoSmithKline; Merck; Roche
Consultant: Aegerion; Amgen; Atherotech; DTC MD; Esperion; iMD (Intelligent Medical Decisions); Kinemed; LipoScience; sanofi-aventis; Synarc; Takeda; Vindico Medical Education; Abbott; Daiichi Sankyo; GlaxoSmithKline; Novo Nordisk; Roche; Professional Evaluation; Vindico
Board of Directors/Equity: DTC MD; Omthera; Professional Evaluation, Inc.; Medical Education Company; Sonogene
Speakers Bureau: Abbott; AstraZeneca; GlaxoSmithKline; Merck

Vivian Fonseca, MD
Grants/Research Support: Novo Nordisk; sanofi-aventis; Eli Lilly; Daiichi Sankyo; Pamlabs; Reata; Halozyme
Consultant: GlaxoSmithKline; Takeda; Novo Nordisk; sanofi-aventis; Eli Lilly; Daiichi Sankyo; Pamlabs; Xoma; AstraZeneca
Speakers Bureau: None

Paul Forfia, MD
Grants/Research Support: None
Consultant: Actelion
Speakers Bureau: Actelion; Gilead; United Therapeutics (formerly)

Thomas Giles, MD
Grants/Research Support: Forest; Novartis
Consultant: Novartis; Forest; NicOx; Takeda; Amylin Pharmaceuticals
Speakers Bureau: Forest

Alan Gradman, MD
Grants/Research Support: Novartis
Consultant: Novartis; Forest; Daiichi Sankyo; Takeda
Speakers Bureau: Novartis; Forest; Daiichi Sankyo; Takeda

Paul Gurbel, MD
Grants/Research Support: Pozen; AstraZeneca; Nanosphere; Accumetrics; Helena; Verum Diagnostica GmbH; Portola; Daiichi Sankyo
Consultant: Pozen; Novartis; Bayer; AstraZeneca; Eli Lilly; Accumetrics; Nanosphere; sanofi-aventis; Boehringer; Merck; Medtronic
Speakers Bureau: None

Edward Horton, MD
Grants/Research Support: Amylin Pharmaceuticals; Eli Lilly
Consultant: Amylin Pharmaceuticals; Gilead; Merck
Speakers Bureau: Merck

Neal Kleiman, MD
Grants/Research Support: None
Consultant: None
Speakers Bureau: None

R. Preston Mason, PhD
Grants/Research Support: Bristol-Myers Squibb; sanofi-aventis; Pfizer; Forest; Novartis
Consultant: Bristol-Myers Squibb; AstraZeneca; Forest
Speakers Bureau: Forest; Pfizer

Mary McGowan, MD
Grants/Research Support: None
Consultant: Genzyme
Speakers Bureau: Merck/Schering-Plough; GlaxoSmithKline

Puja Mehta, MD
Grants/Research Support: Gilead
Consultant: None
Speakers Bureau: None

Luigi Meneghini, MD
Grants/Research Support: Mannkind; Pfizer; Boehringer Ingelheim
Consultant: Novo Nordisk
Speakers Bureau: None

Michael Miller, MD
Grants/Research Support: None
Consultant: Amarin
Speakers Bureau: None

Mark Molitch, MD
Grants/Research Support: Eli Lilly; Reata; Ipsen
Consultant: Abbott Labs; Novartis
Speakers Bureau: None

David Morrow, MD
Grants/Research Support: Accumetrics; AstraZeneca; Bayer Healthcare; Beckman Coulter; Bristol-Myers Squibb; CV Therapeutics; Daiichi Sankyo; Eli Lilly and Co.; Genentech; Johnson & Johnson; Merck and Company; Nanosphere; Novartis Pharmaceuticals; OrthoClinical Diagnostics; Pfizer; Roche Diagnostics; sanofi-aventis; Siemens; Singulex; Schering-Plough
Consultant: AstraZeneca; Beckman-Coulter; Boehringer Ingelheim; Cardiokinetix; Gilead; Ikaria; Instrumentation Laboratory; Menarini; Merck; OrthoClinical Diagnostics; Roche Diagnostics; Schering-Plough Research Institute; Siemens
Speakers Bureau: None

Anne Peters, MD
Grants/Research Support: None
Consultant: Amylin Pharmaceuticals; Eli Lilly; Novo Nordisk; AstraZeneca; Abbott Diabetes Care; Boehringer Ingelheim; Bristol-Myers Squibb; Dexcom; Medtronic Minimed; Merck; Roche, sanofi-aventis
Speakers Bureau: Amylin Pharmaceuticals; Eli Lilly; Takeda; Novo Nordisk

Marc Sabatine, MD, MPH
Grants/Research Support: AstraZeneca; Bristol-Myers Squibb/sanofi-aventis; Daiichi Sankyo; sanofi-aventis; Nanosphere
Consultant: Bristol-Myers Squibb/sanofi-aventis; Daiichi Sankyo/Eli Lilly; sanofi-aventis
Speakers Bureau: None

Jean-Claude Tardif, MD
Grants/Research Support: Genzyme
Consultant: None                                                                                                           
Speakers Bureau: None

Eric Velazquez, MD
Grants/Research Support: Abbott Vascular
Consultant: Novartis; Gilead
Speakers Bureau: Gilead

Carol Wysham, MD
Grants/Research Support: None
Consultant: Amylin Pharmaceuticals; Eli Lilly; Boehringer Ingelheim
Speakers Bureau: Amylin Pharmaceuticals; Eli Lilly; Novo Nordisk; Merck; sanofi-aventis; Boehringer Ingelheim

Bernard Zinman, MD
Grants/Research Support: Novo Nordisk; Merck; Boehringer Ingelheim
Consultant: Novo Nordisk; Merck; Boehringer Ingelheim; Eli Lilly; sanofi-aventis; GlaxoSmithKline; Amylin Pharmaceuticals
Speakers Bureau: None

Educational Supporters
These activities are supported by educational grants from the following:

Platinum Supporters
Novo Nordisk amylin_lilly_logo AstraZeneca
BMS
Gold Supporters
Genzyme Amarin Actelion
Forest Laboratories Inc. Kowa_Lily
daiichi_sankyo_logo Gilead
Silver Supporters
Genentech BoehringerIngelheim    Lilly
Bronze Supporter

Daiichi-Sankyo

I have read the information above and agree to continue with this program  

© 2011 Cardiometabolic Health Congress Home  |  Program Menu  |  Accreditation  |  Credit Instructions  |  Faculty Bios  |  Faculty Disclosures  |  Supporters  |  Edit Profile  |  Contact Us